We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Role of Laminin Defined in Muscular Dystrophy-Related Stem Cell Differentiation

By LabMedica International staff writers
Posted on 13 Jun 2016
The structural protein laminin has been found to play a critical role in determining whether a class of stem cells linked to the development of muscular dystrophy (MD) matures into muscle – which could prevent development of MD – or into fat – which would contribute to the development of MD.

Muscle-resident PDGFRbeta+ cells, which include pericytes and PW1+ interstitial cells (PICs), play a dual role in muscular dystrophy. More...
They can either undergo myogenesis (generation of muscle cells) to promote muscle regeneration or differentiate into adipocytes (fat cells) and other cells to compromise regeneration and drive MD development. However, the factors that regulate the differentiation and fate determination of PDGFRbeta+ cells had not previously been determined. However, previous studies with mouse models had shown that loss of the structural protein laminin contributed to at least some forms of muscular dystrophy.

Investigators at the Rockefeller University (New York, NY, USA) worked with a model system based on genetically engineered conditional knockout mice with laminin deficiency in PDGFRbeta+ cells.

The investigators reported in the May 3, 2016, online edition of the journal Nature Communications that treatment with laminin alone was able to partially reverse the muscle dystrophic phenotype in these mice at the molecular, structural, and functional levels. RNAseq analysis revealed that laminin regulated PDGFRbeta+ cell differentiation and fate determination via the protein gpihbp1 (Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1). This protein is found primarily in capillaries where pericytes reside, and previous research had shown that it was involved in fat metabolism.

Forcing mouse pericytes and PICs that lacked laminin to activate gpihbp1 caused these cells to differentiate preferentially into muscle cells.

"Our data suggests that gpihbp1 could be a novel target for the treatment of muscular dystrophy," said senior author Dr. Sidney Strickland, professor of neurobiology and genetics at the Rockefeller University.

Related Links:
Rockefeller University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.